Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection

Abstract Human respiratory syncytial virus (hRSV) infection is a major pediatric health concern worldwide. Despite more than half a century of efforts, there is still no commercially available vaccine. In this study, we constructed and purified the recombinant protein CTA1-DD-RBF composed of a CTA1-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hai Li, Hu Ren, Yan Zhang, Lei Cao, Wenbo Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9512abb0d1d1466aa2d0fd8aa6ebb7a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9512abb0d1d1466aa2d0fd8aa6ebb7a2
record_format	dspace
spelling	oai:doaj.org-article:9512abb0d1d1466aa2d0fd8aa6ebb7a22021-12-02T15:15:13ZIntranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection10.1038/s41598-021-97535-62045-2322https://doaj.org/article/9512abb0d1d1466aa2d0fd8aa6ebb7a22021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97535-6https://doaj.org/toc/2045-2322Abstract Human respiratory syncytial virus (hRSV) infection is a major pediatric health concern worldwide. Despite more than half a century of efforts, there is still no commercially available vaccine. In this study, we constructed and purified the recombinant protein CTA1-DD-RBF composed of a CTA1-DD mucosal adjuvant and prefusion F protein (RBF) using Escherichia coli BL21 cells. We studied the immunogenicity of CTA1-DD-RBF in mice. Intranasal immunization with CTA1-DD-RBF stimulated hRSV F-specific IgG1, IgG2a, sIgA, and neutralizing antibodies as well as T cell immunity without inducing lung immunopathology upon hRSV challenge. Moreover, the protective immunity of CTA1-DD-RBF was superior to that of the RBF protein, as confirmed by the assessment of serum-neutralizing activity and viral clearance after challenge. Compared to formalin-inactivated hRSV (FI-RSV), intranasal immunization with CTA1-DD-RBF induced a Th1 immune response. In summary, intranasal immunization with CTA1-DD-RBF is safe and effective in mice. Therefore, CTA1-DD-RBF represents a potential mucosal vaccine candidate for the prevention of human infection with hRSV.Hai LiHu RenYan ZhangLei CaoWenbo XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hai Li Hu Ren Yan Zhang Lei Cao Wenbo Xu Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
description	Abstract Human respiratory syncytial virus (hRSV) infection is a major pediatric health concern worldwide. Despite more than half a century of efforts, there is still no commercially available vaccine. In this study, we constructed and purified the recombinant protein CTA1-DD-RBF composed of a CTA1-DD mucosal adjuvant and prefusion F protein (RBF) using Escherichia coli BL21 cells. We studied the immunogenicity of CTA1-DD-RBF in mice. Intranasal immunization with CTA1-DD-RBF stimulated hRSV F-specific IgG1, IgG2a, sIgA, and neutralizing antibodies as well as T cell immunity without inducing lung immunopathology upon hRSV challenge. Moreover, the protective immunity of CTA1-DD-RBF was superior to that of the RBF protein, as confirmed by the assessment of serum-neutralizing activity and viral clearance after challenge. Compared to formalin-inactivated hRSV (FI-RSV), intranasal immunization with CTA1-DD-RBF induced a Th1 immune response. In summary, intranasal immunization with CTA1-DD-RBF is safe and effective in mice. Therefore, CTA1-DD-RBF represents a potential mucosal vaccine candidate for the prevention of human infection with hRSV.
format	article
author	Hai Li Hu Ren Yan Zhang Lei Cao Wenbo Xu
author_facet	Hai Li Hu Ren Yan Zhang Lei Cao Wenbo Xu
author_sort	Hai Li
title	Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
title_short	Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
title_full	Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
title_fullStr	Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
title_full_unstemmed	Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection
title_sort	intranasal vaccination with a recombinant protein cta1-dd-rbf protects mice against hrsv infection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9512abb0d1d1466aa2d0fd8aa6ebb7a2
work_keys_str_mv	AT haili intranasalvaccinationwitharecombinantproteincta1ddrbfprotectsmiceagainsthrsvinfection AT huren intranasalvaccinationwitharecombinantproteincta1ddrbfprotectsmiceagainsthrsvinfection AT yanzhang intranasalvaccinationwitharecombinantproteincta1ddrbfprotectsmiceagainsthrsvinfection AT leicao intranasalvaccinationwitharecombinantproteincta1ddrbfprotectsmiceagainsthrsvinfection AT wenboxu intranasalvaccinationwitharecombinantproteincta1ddrbfprotectsmiceagainsthrsvinfection
_version_	1718387584757923840

Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection

Ejemplares similares